首页> 外文学位 >Strategies to Improve Outcomes in Multiple Myeloma: Preclinical Therapeutics Targeting MEK, HDAC and BCL-2 and Optimizing Autologous Hematopoietic Cell Transplantation

【24h】

Strategies to Improve Outcomes in Multiple Myeloma: Preclinical Therapeutics Targeting MEK, HDAC and BCL-2 and Optimizing Autologous Hematopoietic Cell Transplantation

机译：改善多发性骨髓瘤结果的策略：靶向MEK，HDAC和BCL-2的临床前治疗方法以及优化自体造血细胞移植

获取原文

获取原文并翻译 | 示例

页面导航

著录项
相似文献
相关主题

著录项

作者
Miller, Kevin Charles.;
展开▼
作者单位

College of Medicine - Mayo Clinic.;

展开▼
授予单位 College of Medicine - Mayo Clinic.;
学科
学位 M.S.
年度 2020
页码 102 p.
总页数 102
原文格式 PDF
正文语种 eng
中图分类 AAI27742022;
关键词
Autologous hematopoietic cell transplant; BCL-2; HDAC; Histone deacetylase; MEK; Multiple myeloma;

机译：自体造血细胞移植;BCL-2;HDAC;组蛋白脱乙酰酶;梅克;多发性骨髓瘤;

相似文献

外文文献
中文文献
专利

1. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma [J] . Annals of hematology . 2020,第6期

机译：Pegfilgrastim改善了自体造血干细胞移植治疗多发性骨髓瘤的动员和植入的结果
2. Final outcomes of escalated melphalan 280 mg/m(2) with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival [J] . Hari Parameswaran, Reece Donna E., Randhawa Jasleen, Bone marrow transplantation . 2019,第2期

机译：升级的Melphalan的最终结果280 mg / m（2），具有氨化氨酸细胞保护，遵循多种骨髓瘤的自体造血干细胞移植：高CR和VGPR率不会转化为改善的存活率
3. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years [J] . Auner H. W., Szydlo R., Hoek J., Bone marrow transplantation . 2015,第2期

机译：欧洲多发性骨髓瘤自体造血细胞移植的趋势：近年来老年患者的使用增加和结果改善
4. Intravenous apoptotic cell infusion as a cell-based therapy toward improving hematopoietic cell transplantation outcome [C] . Philippe Saas, Beatrice Gaugler, Sylvain Perruche Conference on Clearance of Dying Cells in a Healthy and Diseased Immune System . 2010

机译：静脉内凋亡细胞输注作为基于细胞的治疗，从而改善造血细胞移植结果
5. Natural Killer Cell Recovery and Disease Outcomes After Autologous Stem Cell Transplantation in Multiple Myeloma [D] . Keruakous, Amany R. 2021

机译：自然杀手细胞回收和疾病结果在多发性骨髓瘤中的自体干细胞移植后
6. Early Relapse after Autologous Hematopoietic Cell Transplantation remains a Poor Prognostic Factor in Multiple Myeloma but Outcomes Have Improved Over Time [O] . Shaji K Kumar, Angela Dispenzieri, Raphael Fraser, -1

机译：自体造血细胞移植后的早期复发仍是多发性骨髓瘤的不良预后因素但随着时间的推移结局得到改善
7. Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival [O] . Parameswaran Hari, Donna E. Reece, Jasleen Randhawa, 2018

机译：升级的Melphalan的最终结果280mg / m 2，具有氨毒素的细胞保护，遵循多种骨髓瘤的自体造血干细胞移植：高Cr和Vgpr率不会转化为改善的存活率

Strategies to Improve Outcomes in Multiple Myeloma: Preclinical Therapeutics Targeting MEK, HDAC and BCL-2 and Optimizing Autologous Hematopoietic Cell Transplantation

著录项

相似文献

相关主题

期刊订阅